Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition.
Saved in:
| Title: | Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. |
|---|---|
| Authors: | Gil Del Alcazar CR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Huh SJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Ekram MB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Trinh A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Liu LL; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts., Beca F; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Zi X; Department of Biomedical Engineering, Yale University, New Haven, Connecticut.; Second Military Medical University, Shanghai, P.R. China., Kwak M; Department of Biomedical Engineering, Yale University, New Haven, Connecticut., Bergholtz H; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Su Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Ding L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Russnes HG; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Richardson AL; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Babski K; Sutter Roseville Medical Center, Roseville, California., Min Hui Kim E; Sutter Roseville Medical Center, Roseville, California., McDonnell CH 3rd; Sutter Roseville Medical Center, Roseville, California., Wagner J; Sutter Roseville Medical Center, Roseville, California., Rowberry R; Sutter Roseville Medical Center, Roseville, California., Freeman GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Dillon D; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Sorlie T; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Coussens LM; Department of Cell, Developmental & Cancer Biology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon., Garber JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Fan R; Department of Biomedical Engineering, Yale University, New Haven, Connecticut., Bobolis K; Sutter Roseville Medical Center, Roseville, California., Allred DC; Department of Pathology, Washington University School of Medicine, St. Louis, Missouri., Jeong J; Department of Surgery, Gangnam Severance Hospital, Yonsei University Medical College, Seoul, Korea., Park SY; Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea., Michor F; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts., Polyak K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. kornelia_polyak@dfci.harvard.edu.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts.; The Broad Institute, Cambridge, Massachusetts.; Harvard Stem Cell Institute, Cambridge, Massachusetts. |
| Source: | Cancer discovery [Cancer Discov] 2017 Oct; Vol. 7 (10), pp. 1098-1115. Date of Electronic Publication: 2017 Jun 26. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
